Sign in
NTLA Stock Price, Chart, Stats & News
Intellia Therapeutics, Inc.
Save
1.80B
Market cap
–
Current P/E
–
Forward P/E
NTLA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -25.55% |
Operating margin | -651.67% |
Pretax margin | -609.85% |
Net margin | -609.85% |
Effective tax rate | – |
ROA | -49.01% |
ROE | -56.63% |
D/E | 0.14x |
Interest coverage ratio | – |
NTLA valuation
P/E | – |
P/S | 21.59x |
P/B | 2.00x |
P/CF | -3.40x |
P/FCF | -3.69x |
P/OCF | -3.40x |
PEG | -0.32x |
EV multiple | -3.65x |
About
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema.
Similar securities
Based on sector and market capitalization
Report issue